Warner Chilcott (NASDAQ:WCRX) Beats Fiscal Fourth Quarter Results – WCRX, ACT, NVS, GSK

The Dublin, Ireland-based Warner Chilcott Plc (NASDAQ:WCRX) announced fiscal Q4 profit hiked from previous year, showing lower costs and sales expenses in many key promoted products, mainly LO Loestrin FE and Asacol. Both adjusted cash EPS and quarterly revenues surpassed analysts’ forecasts.

Specialty pharmaceutical company announced net income of $124 million or $0.49 a share for the Q4, over $90 million or $0.36 a share in the same period previous year.

Thomson Reuters 16 analysts’ survey on average forecasted to announce $0.73 EPS for fiscal Q4. Analysts’ forecasts usually exclude onetime items.

Total revenues for the period tumbled 5% to $612 million from $646 million in the similar period previous year, but surpassed thirteen Wall Street analysts’ median forecast of $565.21 million.

Shifting reader’s focus to broader market, let us consider market performance of other stocks that significantly affect same sector. Actavis Inc (NYSE:ACT) fell -0.37% to settle at $83.44, Novartis AG (ADR) (NYSE:NVS) moved up +0.70% to end at $69.20 while GlaxoSmithKline plc (ADR) (NYSE:GSK) jumped +0.83% to finish at $45.14 on Friday.

Warner Chilcott Plc (NASDAQ:WCRX) on Feb 22, 2013 increased +1.45% to the closing price of $13.96. The overall volume in the last trading session was 3.74 million shares. Its fifty two weeks range was $10.85 – $23.28. The total market capitalization remained at $3.50 billion.

WCRX is ahead of its 52-week low with 28.66% and lagging behind from its 52-week high price with -19.71%. WCRX’s last month’s stock price volatility remained 3.69%. In its share capital WCRX has 250.47 million outstanding shares, among them 245.27 million shares have been floated in market exchange. WCRX’s stock’s institutional ownership remained 92.35% while insider ownership included 1.27%.

The stock price of WCRX is moving down from its 20 days moving average with -0.89% and remote positively from 50 days moving average with 7.00%. WCRX’s current year’s earnings per share experienced an addition with -0.08% while its current quarter performance remained at 22.78%. Company’s beta coefficient included 1.01. Beta factors measure the amount of market risk associated with market trade.

DO NOT TRADE ANY STOCK WITHOUT LEVEL 2 STOCK QUOTES! QuoteDaddy.com delivers it's user with the most in-depth Level 2 Quotation System available on the Planet! NO Downloads, NO Widgets, NO Plugins required! Stay on TOP of your trades with QuoteDaddy.com! CLICK HERE TO START YOUR FREE 30-DAY TRIAL

This entry was posted in Healthcare, Latest Headlines and tagged , , , , , , , , , , , . Bookmark the permalink.